MX2015013092A - Modificación y nuevas composiciones de proteínas secretoglobinas de humano. - Google Patents

Modificación y nuevas composiciones de proteínas secretoglobinas de humano.

Info

Publication number
MX2015013092A
MX2015013092A MX2015013092A MX2015013092A MX2015013092A MX 2015013092 A MX2015013092 A MX 2015013092A MX 2015013092 A MX2015013092 A MX 2015013092A MX 2015013092 A MX2015013092 A MX 2015013092A MX 2015013092 A MX2015013092 A MX 2015013092A
Authority
MX
Mexico
Prior art keywords
protein
isoforms
preparations
novel
novel compositions
Prior art date
Application number
MX2015013092A
Other languages
English (en)
Spanish (es)
Inventor
Melissa E Winn
Richard S Clayton
Humcha K Hariprakasha
Aprile L Pilon
Original Assignee
Therabron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabron Therapeutics Inc filed Critical Therabron Therapeutics Inc
Publication of MX2015013092A publication Critical patent/MX2015013092A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyrrole Compounds (AREA)
MX2015013092A 2013-03-15 2014-03-17 Modificación y nuevas composiciones de proteínas secretoglobinas de humano. MX2015013092A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/843,773 US9394349B2 (en) 2013-03-15 2013-03-15 Modification and compositions of human secretoglobin proteins
PCT/US2014/030117 WO2014145368A2 (en) 2013-03-15 2014-03-17 Modification and novel compositions of human secretoglobin proteins

Publications (1)

Publication Number Publication Date
MX2015013092A true MX2015013092A (es) 2016-06-02

Family

ID=51530119

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013092A MX2015013092A (es) 2013-03-15 2014-03-17 Modificación y nuevas composiciones de proteínas secretoglobinas de humano.

Country Status (13)

Country Link
US (4) US9394349B2 (https=)
EP (2) EP2968449A4 (https=)
JP (2) JP6670987B2 (https=)
KR (1) KR20160030076A (https=)
CN (1) CN105744946A (https=)
AU (1) AU2014233127A1 (https=)
BR (1) BR112015021266A2 (https=)
CA (1) CA2907439A1 (https=)
IL (1) IL241417A0 (https=)
MX (1) MX2015013092A (https=)
RU (1) RU2015144360A (https=)
SG (1) SG11201507277YA (https=)
WO (1) WO2014145368A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12162914B2 (en) 2013-03-15 2024-12-10 Apc Research Assets Llc Modification and compositions of human secretoglobin proteins
US9394349B2 (en) * 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins
JP2018502850A (ja) * 2014-12-22 2018-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗原、抗体を作成するための組成物及び方法、ならびに免疫療法のための組成物及び方法
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
JP2022509856A (ja) * 2018-11-30 2022-01-24 エーピーシー リサーチ アセッツ,エルエルシー ヘパラン硫酸プロテオグリカンタンパク質との相互作用を介してグリコカリックスを保護するためのセクレトグロビンの組成物及び使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1006919A3 (nl) * 1993-03-15 1995-01-24 Ley Marc Jozef Philemon De Farmaceutisch preparaat op basis van clara celeiwit cc10, en het gebruik daarvan als geneesmiddel en diagnosticum.
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US20040047857A1 (en) * 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20030008816A1 (en) 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
WO2000009741A1 (en) 1998-08-13 2000-02-24 The Trustees Of The University Of Pennsylvania Method of identifying proteins
US6953666B1 (en) 1998-11-06 2005-10-11 Emory University Biomarkers for oxidative stress
WO2004101824A1 (ja) 2003-05-14 2004-11-25 Shionogi & Co., Ltd. 慢性閉塞性肺疾患の検出方法
AU2004254600A1 (en) 2003-06-26 2005-01-13 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
CN1580261A (zh) * 2003-08-06 2005-02-16 上海富纯中南生物技术有限公司 Cc10蛋白的制备及应用
JP2007511517A (ja) 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 薬剤と照射を受けた賦形剤の製剤の中の薬剤の酸化を最小化
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US8133859B2 (en) 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
US20090004684A1 (en) 2007-05-23 2009-01-01 Claudia Susanne Maier Compositions and Methods for Detection and Quantification of Protein Oxidation
MX2012004409A (es) * 2009-10-15 2012-08-23 Clarassance Inc Proteina recombinante de humano cc10 para el tratamiento de la influenza.
US9394349B2 (en) * 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins

Also Published As

Publication number Publication date
JP2020055833A (ja) 2020-04-09
US10676513B2 (en) 2020-06-09
CA2907439A1 (en) 2014-09-18
EP2968449A4 (en) 2017-03-22
JP2016515532A (ja) 2016-05-30
SG11201507277YA (en) 2015-10-29
US10294285B2 (en) 2019-05-21
US20140275477A1 (en) 2014-09-18
EP3403666A1 (en) 2018-11-21
AU2014233127A1 (en) 2015-09-24
WO2014145368A2 (en) 2014-09-18
US9394349B2 (en) 2016-07-19
IL241417A0 (en) 2015-11-30
BR112015021266A2 (pt) 2017-10-10
US20200325190A1 (en) 2020-10-15
US20160362462A1 (en) 2016-12-15
JP6670987B2 (ja) 2020-03-25
CN105744946A (zh) 2016-07-06
KR20160030076A (ko) 2016-03-16
EP2968449A2 (en) 2016-01-20
US20190337999A1 (en) 2019-11-07
WO2014145368A3 (en) 2014-11-27
RU2015144360A (ru) 2017-04-24

Similar Documents

Publication Publication Date Title
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
MX2015013092A (es) Modificación y nuevas composiciones de proteínas secretoglobinas de humano.
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
TW200732347A (en) VEGF analogs and methods of use
MX374477B (es) Composicion y productos que comprenden celulas senescentes para su uso en la regeneracion de tejidos
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
TN2012000372A1 (en) Fibronectin based scaffold domain proteins that bind il-23
EA201500261A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
MX2011008094A (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
BR112015022934A8 (pt) esteróides neuroativos, composições e usos destes
UA107706C2 (uk) Апоптоз-індукуючий засіб для лікування раку й імунних і аутоімунних захворювань
MX336489B (es) Hormona foliculo estimulante humana recombinante composicion farmaceutica que la comprende y uso de la misma.
MX2013004726A (es) Anticuerpos dkk1 y metodos de uso.
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
MX2021005843A (es) Composiciones y métodos para aumentar la hemoglobina fetal y tratar la anemia de células falciformes.
TN2013000427A1 (en) Modified acid alpha glucosidase with accelerated processing
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
DE602005026724D1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
EA201190285A1 (ru) Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия
BR112015019568A2 (pt) Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo
BR112013009660A2 (pt) proteína de fusão com fator de atividade ix
MX2018002921A (es) Composicion de hormona foliculo-estimulante mamifera con estabilidad incrementada.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291